noom microdose glp-1 Microdosing meets weight loss as turns a DIY trend into a medical program What if you could start
Description
The 2026 EASO pharmacotherapy update explicitly ranks tirzepatide above semaglutide for weight loss, while supporting semaglutide as the better-documented option for liver fibrosis endpoints in MASH [1]
Injection technique and site impact absorption rates
Robust improvement in glycaemic control (HbA1c) in people with type 2 diabetes, with dose-dependent reductions observed in clinical trials
In percentage terms, VAT reduction averaged 15 to 20 percent over the study period
